50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,631.05 (-0.66%)
DOW   29,032.37 (-0.78%)
QQQ   273.69 (-0.25%)
AAPL   151.05 (+0.19%)
MSFT   235.16 (-0.96%)
META   134.69 (-1.23%)
GOOGL   97.16 (-1.03%)
AMZN   113.77 (-1.20%)
TSLA   278.85 (+1.03%)
NVDA   123.71 (+1.17%)
NIO   17.08 (-3.06%)
BABA   77.69 (-1.55%)
AMD   66.88 (+0.87%)
T   15.72 (+0.32%)
MU   50.28 (+2.86%)
CGC   2.81 (+2.55%)
F   11.75 (-2.00%)
GE   63.78 (-0.89%)
DIS   95.95 (-2.21%)
AMC   7.15 (+4.69%)
PYPL   85.34 (+1.28%)
PFE   44.00 (+0.39%)
NFLX   221.41 (-1.19%)
S&P 500   3,631.05 (-0.66%)
DOW   29,032.37 (-0.78%)
QQQ   273.69 (-0.25%)
AAPL   151.05 (+0.19%)
MSFT   235.16 (-0.96%)
META   134.69 (-1.23%)
GOOGL   97.16 (-1.03%)
AMZN   113.77 (-1.20%)
TSLA   278.85 (+1.03%)
NVDA   123.71 (+1.17%)
NIO   17.08 (-3.06%)
BABA   77.69 (-1.55%)
AMD   66.88 (+0.87%)
T   15.72 (+0.32%)
MU   50.28 (+2.86%)
CGC   2.81 (+2.55%)
F   11.75 (-2.00%)
GE   63.78 (-0.89%)
DIS   95.95 (-2.21%)
AMC   7.15 (+4.69%)
PYPL   85.34 (+1.28%)
PFE   44.00 (+0.39%)
NFLX   221.41 (-1.19%)
S&P 500   3,631.05 (-0.66%)
DOW   29,032.37 (-0.78%)
QQQ   273.69 (-0.25%)
AAPL   151.05 (+0.19%)
MSFT   235.16 (-0.96%)
META   134.69 (-1.23%)
GOOGL   97.16 (-1.03%)
AMZN   113.77 (-1.20%)
TSLA   278.85 (+1.03%)
NVDA   123.71 (+1.17%)
NIO   17.08 (-3.06%)
BABA   77.69 (-1.55%)
AMD   66.88 (+0.87%)
T   15.72 (+0.32%)
MU   50.28 (+2.86%)
CGC   2.81 (+2.55%)
F   11.75 (-2.00%)
GE   63.78 (-0.89%)
DIS   95.95 (-2.21%)
AMC   7.15 (+4.69%)
PYPL   85.34 (+1.28%)
PFE   44.00 (+0.39%)
NFLX   221.41 (-1.19%)
S&P 500   3,631.05 (-0.66%)
DOW   29,032.37 (-0.78%)
QQQ   273.69 (-0.25%)
AAPL   151.05 (+0.19%)
MSFT   235.16 (-0.96%)
META   134.69 (-1.23%)
GOOGL   97.16 (-1.03%)
AMZN   113.77 (-1.20%)
TSLA   278.85 (+1.03%)
NVDA   123.71 (+1.17%)
NIO   17.08 (-3.06%)
BABA   77.69 (-1.55%)
AMD   66.88 (+0.87%)
T   15.72 (+0.32%)
MU   50.28 (+2.86%)
CGC   2.81 (+2.55%)
F   11.75 (-2.00%)
GE   63.78 (-0.89%)
DIS   95.95 (-2.21%)
AMC   7.15 (+4.69%)
PYPL   85.34 (+1.28%)
PFE   44.00 (+0.39%)
NFLX   221.41 (-1.19%)
NASDAQ:AXGN

AxoGen - AXGN Stock Forecast, Price & News

$11.08
+0.06 (+0.54%)
(As of 09/27/2022 02:09 PM ET)
Add
Compare
Today's Range
$11.00
$11.55
50-Day Range
$8.87
$11.74
52-Week Range
$6.87
$16.75
Volume
8,267 shs
Average Volume
215,848 shs
Market Capitalization
$468.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.67

AxoGen MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
46.1% Upside
$16.67 Price Target
Short Interest
Healthy
1.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.10mentions of AxoGen in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$476,841 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.62) to ($0.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

246th out of 1,071 stocks

Electromedical Equipment Industry

4th out of 23 stocks

AXGN stock logo

About AxoGen (NASDAQ:AXGN) Stock

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Receive AXGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter.

AXGN Stock News Headlines

AxoGen, Inc. (AXGN)
Axogen: Q2 Earnings Insights - Benzinga
Read JMP Securities' Take On Axogen's Interim Update
See More Headlines
Receive AXGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter.

AXGN Company Calendar

Last Earnings
8/03/2022
Today
9/27/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXGN
Employees
428
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.67
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+50.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-26,990,000.00
Pretax Margin
-24.68%

Debt

Sales & Book Value

Annual Sales
$127.36 million
Book Value
$2.71 per share

Miscellaneous

Free Float
39,108,000
Market Cap
$468.46 million
Optionable
Optionable
Beta
0.82

Key Executives

  • Ms. Karen ZaderejMs. Karen Zaderej (Age 60)
    Chairman, Pres & CEO
    Comp: $1.16M
  • Mr. Peter J. Mariani (Age 58)
    Exec. VP & CFO
    Comp: $696.4k
  • Ms. Maria D. MartinezMs. Maria D. Martinez (Age 54)
    Chief HR Officer
    Comp: $498.62k
  • Mr. Angelo G. Scopelianos Ph.D. (Age 67)
    Chief R&D Officer
    Comp: $613.99k
  • Mr. Michael Donovan (Age 57)
    VP of Operations
  • Ed Joyce
    Director of Investor Relations
  • Mr. Bradley L. Ottinger J.D. (Age 52)
    Gen. Counsel & Chief Compliance Officer
  • Mr. Gregory Davault (Age 54)
    VP of Marketing
  • Ms. Doris Quackenbush
    VP of Sales
  • Ms. Isabelle Billet (Age 60)
    Chief Strategy & Bus. Devel. Officer













AXGN Stock - Frequently Asked Questions

Should I buy or sell AxoGen stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXGN shares.
View AXGN analyst ratings
or view top-rated stocks.

What is AxoGen's stock price forecast for 2022?

4 Wall Street analysts have issued 12-month price targets for AxoGen's shares. Their AXGN share price forecasts range from $15.00 to $20.00. On average, they expect the company's stock price to reach $16.67 in the next twelve months. This suggests a possible upside of 51.2% from the stock's current price.
View analysts price targets for AXGN
or view top-rated stocks among Wall Street analysts.

How have AXGN shares performed in 2022?

AxoGen's stock was trading at $9.37 at the start of the year. Since then, AXGN shares have increased by 17.6% and is now trading at $11.02.
View the best growth stocks for 2022 here
.

When is AxoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our AXGN earnings forecast
.

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) posted its earnings results on Wednesday, August, 3rd. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.09. AxoGen had a negative trailing twelve-month return on equity of 23.18% and a negative net margin of 24.68%. During the same period in the previous year, the business posted ($0.18) EPS.

What guidance has AxoGen issued on next quarter's earnings?

AxoGen issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $135.00 million-$142.00 million, compared to the consensus revenue estimate of $139.34 million.

What is Karen Zaderej's approval rating as AxoGen's CEO?

19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend.

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

Who are AxoGen's major shareholders?

AxoGen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include First Light Asset Management LLC (7.15%), Point72 Asset Management L.P. (4.93%), William Blair Investment Management LLC (3.90%), State Street Corp (2.18%), Millennium Management LLC (1.28%) and Assenagon Asset Management S.A. (1.23%). Insiders that own company stock include Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan and Peter J Mariani.
View institutional ownership trends
.

How do I buy shares of AxoGen?

Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $11.02.

How much money does AxoGen make?

AxoGen (NASDAQ:AXGN) has a market capitalization of $465.97 million and generates $127.36 million in revenue each year. The medical equipment provider earns $-26,990,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

How many employees does AxoGen have?

The company employs 428 workers across the globe.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The official website for the company is www.axogeninc.com. The medical equipment provider can be reached via phone at (386) 462-6800, via email at investorrelations@axogeninc.com, or via fax at 386-462-6801.

This page (NASDAQ:AXGN) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.